PPIB and Duchenne muscular dystrophy: Having previously proven its potential in human clinical studies confirming the safety and efficacy of plasma-based biomarkers, we recommend that this Neu-REFIX β-glucan be validated in long-term multi-centric clinical studies for its potential as a disease-modifying adjuvant in slowing the progress and increasing the life span of patients with DMD at any stage of the disease.